Skip to main
LIVN
LIVN logo

Livanova (LIVN) Stock Forecast & Price Target

Livanova (LIVN) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

LivaNova has demonstrated robust financial growth, with sales increasing by 29% to $803 million in 2024, highlighting strong market demand for its cardiopulmonary and neuromodulation solutions. The company's management has provided positive guidance, projecting sales to reach between $940 million and $955 million in the near term. Additionally, anticipated growth in the aura6000 device's market share, with revenue estimates ranging from $30 million to $280 million between 2027 and 2029, suggests significant future revenue potential for LivaNova.

Bears say

LivaNova is experiencing significant challenges, with projected revenue growth slowing to low-single digits primarily due to persistent headwinds in its Neuromodulation and Cardiovascular segments. Additionally, the company's operating margins are expected to contract, leading to earnings figures that are likely to fall below analyst consensus. Key risks further complicate the outlook, including potential delays in FDA approvals and slower growth in both Neuromodulation and Cardiopulmonary sectors, alongside anticipated margin improvement that may not materialize as expected.

Livanova (LIVN) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Livanova and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Livanova (LIVN) Forecast

Analysts have given Livanova (LIVN) a Buy based on their latest research and market trends.

According to 7 analysts, Livanova (LIVN) has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $59.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $59.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Livanova (LIVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.